Yes. The Pfizer-BioNTech COVID-19 vaccine for children ages 6 months to 4 years old and the Moderna COVID-19 vaccine for children ages 6 months through 5 years old have lower amounts of mRNA than the Pfizer-BioNTech and Moderna COVID-19 vaccines for people age 12 and older.

The efficacy of the vaccine in preventing symptomatic COVID-19 was 50.6% in children 6 to 23 months of age and 36.8% in children 2 to 5 years of age, starting 14 days after the second dose. The pediatric Moderna COVID-19 vaccine was well tolerated by young children.

Why your child should get vaccinated. Vaccines can prevent common diseases that used to seriously harm or even kill infants, children, and adults. Without vaccines, your child is at risk of becoming seriously ill or even dying from childhood diseases such as measles and whooping cough.

The CDC explained that the Pfizer and Moderna vaccines are preferred due to a greater risk for developing rare but severe blood clots, called thrombosis with thrombocytopenia syndrome (TTS), following administration of the J&J vaccine.

Vaccinations help protect your baby from these diseases:

• Flu (also called influenza).
• Haemophilus influenzae type b (also called Hib).
• Hepatitis A and B.
• Measles, mumps and rubella (also called German measles).
• Pneumococcal disease.
• Polio.
• Rotavirus.
• Tetanus, diphtheria and pertussis.

Pfizer: Is There a “Best” mRNA Vaccine? Both of the mRNA vaccines available in the US are highly effective against severe COVID-19, but recent studies suggest that Moderna's elicits a stronger immune response and might be better at preventing breakthrough infections.

Live-attenuated vaccines Because these vaccines are so similar to the natural infection that they help prevent, they create a strong and long-lasting immune response. Just 1 or 2 doses of most live vaccines can give you a lifetime of protection against a germ and the disease it causes.

Smallpox vaccination with vaccinia virus is the most famous example of a highly effective vaccine and at the time when people were faced with smallpox outbreaks, this vaccine was associated with each of these characteristics that led to the implementation of a successful vaccine.

Moderna's initial Phase 3 clinical data in December 2020 was similar to Pfizer-BioNTech's - both vaccines showed about 95% efficacy for prevention of COVID.

Subunit, recombinant, polysaccharide, and conjugate vaccines One limitation of these vaccines is that you may need booster shots to get ongoing protection against diseases. These vaccines are used to protect against: Hib (Haemophilus influenzae type b) disease.

These include cost, easy administration (e.g. orally), thermal stability, multivalency and long-lived immunlty 2.

Vaccines are the safest of all medications. Before FDA licensing, vaccines are studied in larger populations than are other drugs. Once licensed and put to use, multiple layers of safety surveillance continue as long as the vaccines are distributed.